碳青霉烯耐药肠杆菌目细菌感染归因死亡率:前瞻性多国病例对照匹配队列研究(EURECA)结果
EURECA前瞻性匹配队列研究在50家欧洲医院纳入235例CRE感染、235例CSE感染和705例非感染患者,30天死亡率分别为23.8%、10.6%和8.4%;CRE感染相比CSE感染校正后HR为1.87(95%CI 0.99-3.50,p=0.06),相比非感染患者校正后HR为3.65(95%CI 2.29-5.82,p<0.001)。
要点
- CRE感染30天死亡率为23.8%,CSE感染为10.6%,非感染患者为8.4%。
- CRE较CSE的30天死亡率差值为13.2%(95%CI 6.3-20.0),HR 2.57(95%CI 1.55-4.26,p<0.001)。
- 加入治疗相关时间依赖变量后,CRE vs CSE的HR降至1.44(95%CI 0.78-2.67,p=0.24)。
核心结论
- CRE感染与显著的归因死亡率和升高的校正死亡风险相关,相比CSE感染或非感染患者。
- 患者基础特征和适当治疗的延迟在CRE死亡率中起重要作用。
研究设计与样本
- 前瞻性匹配队列研究(NCT02709408),2016年3月至2018年11月在50家欧洲医院开展。
- CRE队列为复杂尿路感染、复杂腹腔感染、肺炎或其他来源菌血症的CRE感染患者。
- 两个对照队列为碳青霉烯敏感肠杆菌目细菌(CSE)感染患者和无感染患者;匹配标准包括感染类型(CSE组)、CRE检测病房和入院至CRE检测时长。
- 采用多变量和分层Cox回归分析;主要结局为30天死亡率,出院后进行了主动随访。
主要发现
- 队列纳入235例CRE感染、235例CSE感染和705例非感染患者。
- 30天死亡率(95%CI)分别为23.8%(18.8-29.6)、10.6%(7.2-15.2)和8.4%(6.5-10.6)。
- CRE感染较CSE感染的30天死亡率差值为13.2%(95%CI 6.3-20.0),HR 2.57(95%CI 1.55-4.26,p<0.001);较非感染患者的差值为15.4%(95%CI 10.5-20.2),HR 3.85(95%CI 2.57-5.77,p<0.001)。
- CRE vs CSE的30天死亡率人群归因分数为19.28%,CRE vs 非感染患者为9.61%。
- 基线变量校正后,HR分别为1.87(95%CI 0.99-3.50,p=0.06)和3.65(95%CI 2.29-5.82,p<0.001);加入治疗相关时间依赖变量后,CRE vs CSE的HR降至1.44(95%CI 0.78-2.67,p=0.24)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and to investigate the effect of clinical management on differences in observed outcomes in a multinational matched cohort study. METHODS: A prospective matched-cohorts study (NCT02709408) was performed in 50 European hospitals from March 2016 to November 2018. The main outcome was 30-day mortality with an active post-discharge follow-up when applied. The CRE cohort included patients with complicated urinary tract infections, complicated intra-abdominal infections, pneumonia, or bacteraemia from other sources because of CRE. Two control cohorts were selected: patients with infection caused by carbapenem-susceptible Enterobacterales (CSE) and patients without infection. Matching criteria included type of infection for the CSE group, hospital ward of CRE detection, and duration of hospital admission up to CRE detection. Multivariable and stratified Cox regression was applied. RESULTS: The cohorts included 235 patients with CRE infection, 235 patients with CSE infection, and 705 non-infected patients. The 30-day mortality (95% CI) was 23.8% (18.8-29.6), 10.6% (7.2-15.2), and 8.4% (6.5-10.6), respectively. The difference in 30-day mortality rates between patients with CRE infection when compared with patients with CSE infection was 13.2% (95% CI, 6.3-20.0), (HR, 2.57; 95% CI, 1.55-4.26; p < 0.001), and 15.4% (95% CI, 10.5-20.2) when compared with non-infected patients (HR, 3.85; 95% CI, 2.57-5.77; p < 0.001). The population attributable fraction for 30-day mortality for CRE vs. CSE was 19.28%, and for CRE vs. non-infected patients was 9.61%. After adjustment for baseline variables, the HRs for mortality were 1.87 (95% CI, 0.99-3.50; p 0.06) and 3.65 (95% CI, 2.29-5.82; p < 0.001), respectively. However, when treatment-related time-dependent variables were added, the HR of CRE vs. CSE reduced to 1.44 (95% CI, 0.78-2.67; p 0.24). DISCUSSION: CRE infections are associated with significant attributable mortality and increased adjusted hazard of mortality when compared with CSE infections or patients without infection. Underlying patient characteristics and a delay in appropriate treatment play an important role in the CRE mortality.
引用
- Paniagua-García M, Bravo-Ferrer JM, Pérez-Galera S, et al. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA). Clin Microbiol Infect. 2024. PMID: 38267096. doi:10.1016/j.cmi.2023.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。